Stephens raised the firm’s price target on Natera (NTRA) to $235 from $17 and keeps an Overweight rating on the shares after the company reported “another strong beat.” The firm continues to view Natera as “one of the most attractive organic growth stories” within diagnostics, the analyst tells investors.
TipRanks Black Friday Sale
- Claim 60% off TipRanks Premium for the data-backed insights and research tools you need to invest with confidence.
- Subscribe to TipRanks' Smart Investor Picks and see our data in action through our high-performing model portfolio - now also 60% off
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on NTRA: